A Curated Platform of Equity & Options Market Intelligence
Select Page

FGEN

Search by
TICKER SYMBOL

FibroGen Inc

Sector: Professional, Scientific, and Technical Services
Industry: Research and Development in Biotechnology (except Nanobiotechnology)

1.3

-0.06

(-4.412%)

Volume:

0

52 week range:

0.3333 - 20.9

Market Cap:

128.403M

Company Description:

fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com.